PI3K inhibitors for ER + BC include pan-class I PI3K inhibitors targeting the p110α, p110β, p110γ and p110δ isoforms (buparlisib and pictilisib), as well as selective PI3K p110α inhibitors (alpelisib and taselisib) [4]. Here, PIK3CD is linked to breast cancer.